FOR DOCTORS & PHYSICIAN-LED BRANDS
Custom Supplement Manufacturing for Doctors & Physician-Led Brands
Custom development, evidence-led decision support, contracted deliverables and a route to production without owning a factory.
Build a clinically defensible physician-led brand without taking on factory operations. We scope the work through Paid Discovery boundaries, then execute evidence-led formulation and governed production around your clinical and commercial goals.
THE PHYSICIAN BUYER JOB
Before formulation starts, we de-risk six exposure zones: patient and reputation risk, evidence quality, formulation differentiation, ingredient and production quality, regulatory responsibility, and operational burden.
The Market Shift
Why physician-led brands need a governed development route.
Clinical credibility is now priced as an enterprise asset, not a marketing angle.
Physician-led programmes need clear decisions on evidence, product specification, quality controls, target market and commercial route before production is considered.
For a physician-led brand, patient trust, evidence quality, regulatory responsibility and operating burden remain buyer decisions. A CDMO relationship must make those boundaries explicit rather than obscure them with generic claims.
Olympia uses a governed intake and execution process so physician teams can make evidence-led decisions before committing to production scope.
Quality Architecture
What defines our quality architecture
Our production protocols apply documented quality controls across every project. Each custom supplement formulation is built under defined GMP and analytical standards, not assembled from catalogue inputs.
HPLC/GC-MS Verification
Analytical verification methods including high-performance liquid chromatography and gas chromatography-mass spectrometry are applied in our quality programme. Certificate of Analysis details are defined in the project scope and governed by IOC laboratory protocols.
Formulation Interaction Review
After our R&D team designs your formula, our formulation review process includes screening for known ingredient interactions and combination effects as part of the development workflow.
Featured in Forbes ›Evidence-Informed Dosage Parameters
Dosage parameters are assessed against the agreed evidence boundary, formulation feasibility and the intended market. They are not selected from a catalogue or presented as a guaranteed outcome.
Contracted Formulation IP Rights
Every formula is built from scratch for your project. Contracted formulation IP rights transfer to you as defined in the project agreement — not retained by Olympia Biosciences™.
Claims Substantiation
Evidence and claim boundaries before market entry.
A physician-led supplement programme needs an evidence boundary before public claims are drafted. Any external testing, substantiation or lab work is separately scoped; it is never presumed to be included in formulation or manufacturing.
Corneometry & Skin Hydration
Where a project requires skin-related evidence, the measurement method, intended wording and validation owner must be defined before external work is commissioned.
Tewametry (TEWL)
Evidence planning for barrier-function positioning requires a defined method, target market and claim boundary; visual marketing alone is not evidence.
Metabolic & Biomarker Panels
Metabolic or biomarker work, where appropriate, must be designed as a separate evidence programme with its own protocol, provider, market and approval boundary.
Structure-Function Claim Architecture
Supplements cannot claim to cure, treat or prevent disease. Claim wording, documentation support and labelling review are assessed for the named market and agreed scope; final compliance responsibility remains with the brand owner.
Evidence-Based Literature Review Support
For physician-led programmes, we can structure the literature-review method behind the scientific assessment: defining the research question, relevant population, intervention boundary, comparator logic and outcome hierarchy before public claims are drafted.
Methodology Before Substantiation Spend
This research-services layer helps a medical brand identify evidence gaps, endpoint mismatches and study-quality limitations early, so external substantiation, clinical planning and regulatory documentation are commissioned against a defined scientific method rather than intuition.
Formulation Intelligence
What separates a clinical formula from a catalogue product.
Physician-grade formulations require more than ingredient selection. Three technical factors determine whether a formula delivers its clinical promise.
Branded Clinically Studied Ingredients
We source branded, clinically studied actives — such as KSM-66® Ashwagandha (the world's most studied full-spectrum root extract) and Cognizin® citicoline (backed by human clinical trials) — rather than generic powders with no clinical evidence base.
Optimised Bioavailability
Nutrient form determines absorption. We formulate with chelated mineral forms, liposomal delivery systems, and phospholipid complexes where evidence supports superior bioavailability over conventional salts.
Synergistic Blend Architecture
Ingredients that potentiate each other are intentionally co-formulated. Synergistic ratios are validated against published pharmacokinetic data, not assembled by marketing intuition.
Clean Labelling
No artificial fillers, titanium dioxide, magnesium stearate alternatives where clinically indicated, and full allergen disclosure. Patient trust begins at the label.
Turnkey Execution
Clinical asset admission framework
Physician mandates are evaluated, de-risked, and scaled through a gated six-step diligence model:
Programme Scoping
Share the product and commercial brief. Paid Discovery defines the evidence, ingredient, market and formulation questions that must be resolved before a technical work scope is agreed.
Custom Formulation Review
The formulation route and delivery system are selected against the agreed technical brief. The development workflow includes review of known ingredient-interaction considerations.
GMP Production
Manufacturing is planned under the documented quality systems and scope confirmed for the project. Production scale follows the agreed commercial and technical requirements.
Analytical Verification
Analytical methods and Certificate of Analysis deliverables are determined by product risk, target market and the agreed quality scope.
Regulatory Documentation Support
We support regulatory documentation preparation for defined markets — including labelling review and notification assistance — within the scope confirmed in the project agreement. Final regulatory responsibility remains with the brand owner.
Contracted Rights & Production Planning
Contracted formulation deliverables and rights are defined in the project agreement. Production planning proceeds only when technical scope and commercial terms are agreed.
Financial Architecture
Manufacturing Costs:
CAPEX vs. OPEX
Building your own production facility requires massive capital expenditure (CAPEX): GMP-compliant clean rooms, analytical equipment, regulatory certifications, and specialized personnel. For most medical practices, this is neither practical nor financially rational.
Working with a nutraceutical CDMO like Olympia Biosciences™ converts this into operational expenditure (OPEX). You pay for formulation development and per-unit production — without the infrastructure burden. This model allows physicians to launch premium supplement brands with manageable investment and defined unit economics.
The CAPEX Trap
Millions frozen in infrastructure, clean rooms, and compliance audits before a single bottle is sold. Significant operational and regulatory risk.
The CDMO OPEX Advantage
Pay only for R&D and finished, validated products. Zero infrastructure risk. Quality systems and scalability are built into the manufacturing model — regulatory scope is defined per project.
R&D Discovery Investment
PAID DISCOVERY
Paid due diligence entry allocation for qualified physician and clinic mandates
Qualified physician mandates begin with a paid strategic due-diligence allocation. Total technical execution scope is defined by formulation complexity, regulatory burden, and validated enterprise scale pathway.
Launch Protocol
Physician supplement launch: the critical factors.
To successfully launch or scale a physician-branded dietary supplement line through a CDMO, four domains must be validated before production commitment.
1. The Right Formulations
- Branded, clinically studied active ingredients (KSM-66® Ashwagandha, Cognizin®) — not generic powders
- Most absorbable nutrient forms: chelated minerals, liposomal delivery, phospholipid complexes
- Synergistic blends validated against pharmacokinetic evidence — demonstrating clinical authority
2. Certifications & Quality Controls
- GMP / ISO 22000 / HACCP certified manufacturing facility — not self-declared compliance
- Certificate of Analysis and verification requirements defined by product risk, target market and the agreed quality scope
- Clean labelling: no artificial fillers, binders, or allergens — matching professional-grade patient trust standards
3. Smart Manufacturing Logistics
- Practical validation work is separately scoped and prepaid — production scale follows validated commercial fit
- Preferred delivery format expertise: high-tech liquid sachets, vegan capsules, enteric-coated tablets, or softgels
- The project agreement defines formulation deliverables, rights and confidentiality boundaries
4. Claims & Compliance Architecture
- No disease claims — even as a physician, supplements cannot claim to cure, treat, or prevent any condition
- Structure-function framing: e.g., "supports cardiovascular health", "promotes cognitive function"
- Regulatory documentation support, labelling review and notification assistance are defined per target market and contracted scope
Our Partners
Medical Specialties We Serve
We also partner with healthcare-focused venture capital funds seeking to build portfolio supplement brands with genuine clinical differentiation.
Our IP Pledge
We do not own consumer brands.
No consumer supplement brands in the Olympia Biosciences™ portfolio.
Olympia Biosciences™ does not operate consumer supplement brands. Confidentiality, contracted formulation deliverables and applicable rights are defined in the project agreement and supported by the documented information-security framework.
Ready to move from clinical concept to governed production?
Start with the paid boundary, review legal and quality evidence, and define contracted deliverables before scale-up.
RELATED INTELLIGENCE
Frequently Asked Questions
What makes Olympia Biosciences™ different from standard supplement manufacturers?
How is production scale determined for physician-led clinical mandates?
What regulatory support does Olympia Biosciences™ provide for physician supplement brands?
Can physicians use Olympia Biosciences™ to create EBM (Evidence-Based Medicine) supplement formulas?
What is the admission process for a physician or clinic mandate at Olympia Biosciences™?
Does Olympia Biosciences™ manufacture supplements for functional medicine practices?
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.